Search our Database of Scientific Publications and Authors

I’m looking for a

    854 results match your criteria Congenital Erythropoietic Porphyria

    1 OF 18

    Delayed photosensitivity in a child with erythropoietic protoporphyria : a case report.
    SAGE Open Med Case Rep 2018 23;6:2050313X18772125. Epub 2018 May 23.
    Dalhousie University, Halifax Regional Municipality, Canada.
    Erythropoietic protoporphyria (EPP) is a genetically inherited disease that causes protoporphyrin accumulation in erythrocytes, skin, liver, bile, and stool. Clinically this manifests as photosensitivity with painful, edematous cutaneous porphyria. We present the case of a four-year-old boy with a delayed photosensitivity reaction to sunlight. Read More

    Brain perfusion defects by SPET/CT and neurostat semi-quantitative analysis in two patients with congenital erythropoietic porphyria.
    Hell J Nucl Med 2018 Jan-Apr;21(1):43-47
    Nuclear Medicine, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy.
    Background: Congenital erythropoietic porphyria (CEP) is a rare autosomal recessively inherited disorder with chronic and relatively stable presentation. Till now brain blood flow derangements have been described only in acute hepatic porphyrias. We describe the first findings of brain perfusion defects, studied by single photon emission tomography/computed tomography (SPET/CT), in two patients affected by CEP, by using a semi-quantification anatomic-standardized voxel-based program compared with magnetic resonance imaging (MRI) results. Read More

    Erythropoietic Protoporphyria: Initial Diagnosis With Cholestatic Liver Disease.
    Pediatrics 2018 Apr;141(Suppl 5):S445-S450
    Departments of Pathology and Immunology and
    The porphyrias are a group of rare metabolic disorders that result from defects in heme biosynthesis. Erythropoietic protoporphyria (EPP) is the most common inherited porphyria in children and is diagnosed in most individuals after the onset of cutaneous manifestations. Hepatobiliary disease affects the minority of individuals with EPP and usually manifests in patients with an established diagnosis of EPP. Read More

    [Congenital erythropoietic porphyria: case report and management recommendations].
    Arch Argent Pediatr 2018 Apr;116(2):e300-e302
    División de Pediatría, Pontificia Universidad Católica de Chile, Santiago, Chile.
    Congenital erythropoietic porphyria is an extremely rare, autosomal recessive, non-acute cutaneous porphyria, caused by uroporphyrinogen III synthase deficiency, codificated by UROS gene on the chromosome 10q26.2. Porphyrins deposit in cornea, bones and teeth. Read More

    Porphyria: What Is It and Who Should Be Evaluated?
    Rambam Maimonides Med J 2018 04 19;9(2). Epub 2018 Apr 19.
    Porphyria Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel.
    The porphyrias are a group of rare metabolic disorders, inherited or acquired, along the heme biosynthetic pathway, which could manifest with neurovisceral and/or cutaneous symptoms, depending on the defective enzyme. Neurovisceral porphyrias are characterized by acute attacks, in which excessive heme production is induced following exposure to a trigger. An acute attack usually presents with severe abdominal pain, vomiting, and tachycardia. Read More

    Prevention of photosensitivity with action spectrum adjusted protection for erythropoietic protoporphyria.
    J Dermatol 2018 Feb 20;45(2):145-149. Epub 2017 Dec 20.
    Department of Dermatology, Kindai University Faculty of Medicine, Osaka, Japan.
    Erythropoietic protoporphyria is a genetic disease characterized by sensitivity to sunlight caused by the accumulation of protoporphyrin IX. Photoprotection against ultraviolet A and visible light is necessary for erythropoietic porphyria patients because the absorption spectrum of protoporphyrin IX lies in both ultraviolet A and visible light region. We developed a novel index, in vitro porphyrin protection factor, based on the protoporphyrin IX absorbance spectrum. Read More

    An overview of the cutaneous porphyrias.
    F1000Res 2017 30;6:1906. Epub 2017 Oct 30.
    Scottish Cutaneous Porphyria Service, Scottish Photodiagnostic Unit, Department of Dermatology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK.
    This is an overview of the cutaneous porphyrias. It is a narrative review based on the published literature and my personal experience; it is not based on a formal systematic search of the literature. The cutaneous porphyrias are a diverse group of conditions due to inherited or acquired enzyme defects in the porphyrin-haem biosynthetic pathway. Read More

    Neonatal hemolytic anemia does not always indicate thalassemia: a case report.
    BMC Res Notes 2017 Sep 12;10(1):476. Epub 2017 Sep 12.
    Department of Medicine, School of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen.
    Background: Congenital erythropoietic porphyria is a rare autosomal recessive disorder that affects heme-porphyrin synthesis. This disorder is due to the genetic defect of uroporphyrinogen III cosynthase. This defect results in the accumulation of high amounts of uroporphyrin I in all tissues, leading to clinical manifestations ranging from mild to severe chronic damage of the skin, cartilage and bone. Read More

    Mutation in human elevates levels of aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria.
    Proc Natl Acad Sci U S A 2017 09 5;114(38):E8045-E8052. Epub 2017 Sep 5.
    Division of Hematology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115;
    Loss-of-function mutations in genes for heme biosynthetic enzymes can give rise to congenital porphyrias, eight forms of which have been described. The genetic penetrance of the porphyrias is clinically variable, underscoring the role of additional causative, contributing, and modifier genes. We previously discovered that the mitochondrial AAA+ unfoldase ClpX promotes heme biosynthesis by activation of δ-aminolevulinate synthase (ALAS), which catalyzes the first step of heme synthesis. Read More

    Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report.
    Br J Dermatol 2017 Sep 2. Epub 2017 Sep 2.
    Department of Haematology, Hospital Clínic of Barcelona, University of Barcelona, Spain.
    Congenital erythropoietic porphyria is a rare autosomal recessive disease caused by a deficiency of uroporphyrinogen III synthase, owing to mutations in UROS in chromosome 10. Occasionally, patients show a mild, late-onset disease, without germline UROS mutations, associated with haematological malignancies. We report a 65-year-old patient with photosensitivity, overexcretion of porphyrins and thrombocytopenia. Read More

    N Engl J Med 2017 Aug;377(9):862-872
    From the Department of Medicine, Division of Gastroenterology and Porphyria Center, University of California, San Francisco, San Francisco (D.M.B.); the Departments of Preventive Medicine and Community Health and Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston (K.E.A.); and the Department of Gastroenterology, Wake Forest School of Medicine, Winston-Salem, NC (H.L.B.).

    Osteoporosis in patients with erythropoietic protoporphyria.
    Br J Dermatol 2017 Dec 22;177(6):1693-1698. Epub 2017 Nov 22.
    Department of Internal Medicine, Porphyria Centre, Centre for Lysosomal and Metabolic Diseases, Erasmus MC, PO Box 2040, 3000, CA Rotterdam, the Netherlands.
    Background: Erythropoietic protoporphyria (EPP) is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation.

    Objectives: To evaluate bone mineral density (BMD) and known osteoporosis risk factors in patients with EPP.

    Methods: Patients with EPP attending the Erasmus MC outpatient clinic who had undergone BMD measurements were included. Read More

    Neonatal-Onset Hereditary Coproporphyria: A New Variant of Hereditary Coproporphyria.
    JIMD Rep 2017 28;37:99-106. Epub 2017 Mar 28.
    Department of Pediatrics, Okayama University Hospital, Shikatacho 2-5-1, Kita-ku, Okayama, 700-8558, Japan.
    Genetic mutation of the coproporphyrinogen oxidase (CPOX) gene causes either hereditary coproporphyria (HCP) or harderoporphyria. HCP, a rare hepatic porphyria, causes acute attacks after puberty and rarely accompanies cutaneous symptoms. In contrast, harderoporphyria is an erythropoietic porphyria that represents photosensitivity and hemolytic anemia from the neonatal period. Read More

    Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
    Hum Mol Genet 2017 04;26(8):1565-1576
    Université de Bordeaux.
    Congenital erythropoietic porphyria (CEP) is an inborn error of heme biosynthesis characterized by uroporphyrinogen III synthase (UROS) deficiency resulting in deleterious porphyrin accumulation in blood cells responsible for hemolytic anemia and cutaneous photosensitivity. We analyzed here the molecular basis of UROS impairment associated with twenty nine UROS missense mutations actually described in CEP patients. Using a computational and biophysical joint approach we predicted that most disease-causing mutations would affect UROS folding and stability. Read More

    Congenital erythropoietic porphyria (Gunther disease) - long-term follow up of a case and review.
    Dermatol Online J 2017 Feb 15;23(2). Epub 2017 Feb 15.
    St Vincent's Hospital, Melbourne, Victoria, Australia. matthew.david.
    Patients with the rare genodermatosis congenitalerythropoietic porphyria (CEP, Gunther disease)develop erosions and scarring on sun-exposedsites caused by phototoxin mediated damage.Compromised skin barrier function places patientsat higher risk of infection and long term sequelaeinclude scarring. We report a long term follow up ofa 60 year old patient born with CEP and provide anextensive literature review of CEP including recentupdates on potential management options. Read More

    Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity.
    J Inherit Metab Dis 2017 05 9;40(3):433-441. Epub 2017 Feb 9.
    Porphyria Centre San Gallicano Dermatological Institute IRCCS, Rome, Italy.
    Patients with erythropoietic protoporphyria (EPP) have reduced activity of the enzyme ferrochelatase that catalyzes the insertion of iron into protoporphyrin IX (PPIX) to form heme. As the result of ferrochelatase deficiency, PPIX accumulates and causes severe photosensitivity. Among different patients, the concentration of PPIX varies considerably. Read More

    Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Günther disease model.
    Haematologica 2017 02 10;102(2):260-270. Epub 2016 Nov 10.
    INSERM U1149/ERL CNRS 8252, Centre de Recherche sur l'Inflammation Paris Montmartre, 75018 Paris, France
    Hemolysis occurring in hematologic diseases is often associated with an iron loading anemia. This iron overload is the result of a massive outflow of hemoglobin into the bloodstream, but the mechanism of hemoglobin handling has not been fully elucidated. Here, in a congenital erythropoietic porphyria mouse model, we evaluate the impact of hemolysis and regenerative anemia on hepcidin synthesis and iron metabolism. Read More

    Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments.
    Curr Opin Hematol 2017 May;24(3):198-207
    aINSERM U1149 CNRS ERL 8252, Centre de Recherche sur l'inflammation, Université Paris Diderot, site Bichat, Sorbonne Paris Cité bLaboratory of excellence, GR-Ex, Paris cAP-HP, Centre Français des Porphyries, Hôpital Louis Mourier, Colombes dAP-HP, Hôpital Beaujon, Service de Biochimie Clinique, Clichy, France.
    Purpose Of Review: Many studies over the past decade have together identified new genes including modifier genes and new regulation and pathophysiological mechanisms in inherited inborn diseases of the heme biosynthetic pathway. A new porphyria has been characterized: X-linked protoporphyria and the perspective to have innovative treatment at very short-term became a reality. We will summarize how recent data on both ALAS1 and ALAS2 have informed our understanding of disease pathogenesis with an emphasis on how this information may contribute to new therapeutic strategies. Read More

    Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.
    Dis Model Mech 2017 03 12;10(3):225-233. Epub 2017 Jan 12.
    Institute of Laboratory Medicine, Municipal Hospital Triemli, Zürich 8063, Switzerland
    Erythropoietic protoporphyria (EPP) is caused by deficiency of ferrochelatase (FECH), which incorporates iron into protoporphyrin IX (PPIX) to form heme. Excitation of accumulated PPIX by light generates oxygen radicals that evoke excessive pain and, after longer light exposure, cause ulcerations in exposed skin areas of individuals with EPP. Moreover, ∼5% of the patients develop a liver dysfunction as a result of PPIX accumulation. Read More

    Erythropoietic protoporphyria a clinical and molecular study from Lebanon: Ferrochelatase a potential tumor suppressor gene in colon cancer.
    Clin Genet 2017 Nov 2;92(5):495-502. Epub 2017 Aug 2.
    Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon.
    Erythropoietic protoporphyria (EPP) is a rare cutaneous and systemic disease caused by mutations in the ferrochelatase gene (FECH). The molecular underpinnings of EPP in Middle Eastern populations and relative to other ethnic groups secondary to increased consanguinity are unknown. To understand the molecular pathogenesis of Middle Eastern EPP, we surveyed clinicopathological and molecular features in 6 large consanguineous families from Lebanon and Syria presenting with cutaneous and systemic features consistent with EPP. Read More

    Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.
    Clin Pharmacokinet 2017 Aug;56(8):815-823
    Stadtspital Triemli, Institute of Laboratory Medicine, Zurich, Switzerland.
    Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation. The loss-of-function variants of the MC1R present in fair-skinned Caucasians are less effectively activated by the natural hormone. Read More

    Advances in the management of erythropoietic protoporphyria - role of afamelanotide.
    Appl Clin Genet 2016 12;9:179-189. Epub 2016 Dec 12.
    Department of Internal Medicine, Section on Gastroenterology.
    Erythropoietic protoporphyria (EPP) and the phenotypically similar disease X-linked protoporphyria (XLPP) are inherited cutaneous porphyrias characterized clinically by acute non-blistering photosensitivity, intolerance to sunlight, and significantly reduced quality of life. They are due to marked overproduction of protoporphyrin (PP) chiefly by erythroblasts and reticulocytes. In EPP, the underlying genetic defect is in the ferrochelatase gene, which encodes the final enzyme in the heme synthetic pathway. Read More

    Photodermatoses: Kids are not just little people.
    Clin Dermatol 2016 Nov - Dec;34(6):724-735. Epub 2016 Jul 12.
    University of Connecticut School of Medicine, Department of Dermatology, Farmington, CT.
    Photodermatoses are a group of skin disorders caused by abnormal reaction to ultraviolet radiation. Photodermatoses are divided into four groups: (1) immunologically mediated photodermatoses; (2) chemical- and drug-induced photodermatoses; (3) photoaggravated dermatoses; and (4) hereditary photodermatoses. This contribution discusses differences in the approach and diagnosis of pediatric and adult patients with suspected photodermatoses, focusing on immunologically mediated photodermatoses and chemical- and drug-induced photodermatoses. Read More

    Case Report of Patient With Erythropoietic Protoporphyria and Basal Cell Carcinoma Diagnoses.
    J Cutan Med Surg 2017 May/Jun;21(3):258-260. Epub 2016 Nov 12.
    2 Department of Internal Medicine, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
    Background: Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. There is a clear association between BCC development and ultraviolet (UV) radiation. Erythropoietic protoporphyria (EPP) is an inherited porphyria disorder that is a result of protoporphyrin accumulation, typically manifesting with phototoxicity. Read More

    Hepatic porphyria: A narrative review.
    Indian J Gastroenterol 2016 Nov 31;35(6):405-418. Epub 2016 Oct 31.
    Department of Internal Medicine, UAB University of Alabama in Birmingham, Birmingham, AL, USA.
    Porphyrias are a group of metabolic disorders, which result from a specific abnormality in one of the eight enzymes of the heme biosynthetic pathway. These have been subdivided based on the predominant site of enzyme defect into hepatic and erythropoietic types and based on clinical presentation into acute neurovisceral and cutaneous blistering porphyrias. This review focuses on hepatic porphyrias, which include acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), aminolevulinic acid dehydratase deficiency porphyria (ADP), and porphyria cutanea tarda (PCT). Read More

    Clinical, Biochemical and Molecular Characteristics of the Main Types of Porphyria.
    Adv Clin Exp Med 2016 Mar-Apr;25(2):361-8
    Department of Haemostasis and Metabolic Disorders of the Institute of Haematology and Transfusion Medicine, Warszawa, Poland.
    Porphyrias are diverse disorders that arise from various inherited enzyme defects in the heme biosynthesis pathway, except for porphyria cutanea tarda (PCT), in which the enzyme deficiency in most cases is acquired. The biosynthetic blocks resulting from the defective enzymes are largely expressed either in the liver or bone marrow, the sites where the majority of heme is produced. Although the pathophysiologic mechanisms of the clinical manifestations of the porphyrias are not fully understood, two cardinal features prevail: skin photosensitivity and neurologic symptoms of intermittent autonomic neuropathy, acute neurovisceral attacks, and disorders of the nervous system. Read More

    Perianal Ulceration in a Young Woman.
    Am J Dermatopathol 2016 Sep;38(9):683-4
    *University of Illinois College of Medicine at Peoria, Peoria, IL; Departments of †Dermatology, and ‡Pathology, University of Mississippi Medical Center, Jackson, MS; and §Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY.

    Congenital Erythropoietic Porphyria with Undescended Testis.
    Indian J Dermatol 2016 Jul-Aug;61(4):467
    Department of Dermatology, Army College of Medical Sciences, New Delhi, India.
    Hereditary porphyrias are a group of metabolic disorders of heme biosynthesis pathway that are characterized by acute neurovisceral symptoms, skin lesions, or both. Congenital erythropoietic porphyria (CEP) is an extremely rare disease with a mutation in the gene that codes for uroporphyrinogen III synthase leading to accumulation of porphyrin in different tissues and marked cutaneous photosensitivity. We report a case of CEP with infancy onset blistering, photosensitivity, red colored urine, and teeth along with scarring. Read More

    Novel Treatment Using Cimetidine for Erythropoietic Protoporphyria in Children.
    JAMA Dermatol 2016 11;152(11):1258-1261
    Department of Dermatology, Stanford University, Stanford, California.
    Importance: Erythropoietic protoporphyria (EPP) is a rare hereditary disease of heme biosynthesis that manifests as severe photosensitivity and hepatotoxicity. There have been no effective treatments to date. Cimetidine has been shown to inhibit heme biosynthesis and results in symptomatic improvement in patients with acute intermittent porphyria (AIP) and porphyria cutanea tarda (PCT). Read More

    A case of erythropoietic protoporphyria.
    Proc (Bayl Univ Med Cent) 2016 Jul;29(3):311-2
    Department of Pathology, University of South Carolina, Charleston (Lindsey); and the Departments of Hematology/Oncology (Burch) and Pathology (Krause), Baylor University Medical Center at Dallas and Baylor Sammons Cancer Center, Dallas, Texas.
    A 53-year-old Texas rancher developed a blistering skin rash that was sensitive to exposure to sunlight. He was referred to hematology with a presumptive diagnosis of porphyria. His peripheral blood counts were within normal limits, and a bone marrow examination revealed erythroid dyspoiesis and ringed sideroblasts. Read More

    Cutaneous Porphyrias: Causes, Symptoms, Treatments and the Danish Incidence 1989-2013.
    Acta Derm Venereol 2016 Nov;96(7):868-872
    Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 5000 Odense C, Denmark.
    Porphyrias are rare diseases caused by altered haem synthesis leading to the accumulation of different haem intermediates. Neurovisceral attacks may occur in acute porphyrias, while photosensitivity is the presenting symptom in cutaneous porphyrias. We present here an overview of symptoms and a flowchart for the diagnosis of cutaneous porphyrias, with recommendations for monitoring and an update of treatment options. Read More

    Late-onset cutaneous porphyria in a patient heterozygous for a uroporphyrinogen III synthase gene mutation.
    Br J Dermatol 2016 Dec 11;175(6):1346-1350. Epub 2016 Aug 11.
    Departments of Dermatology, Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain.
    Deficiency of uroporphyrinogen III synthase (UROS) causes congenital erythropoietic porphyria (CEP). The disease, originating from the inheritance of mutations within the UROS gene, presents a recessive form of transmission. In a few patients, a late-onset CEP-like phenotype without UROS mutations appears to be associated with a myelodysplastic syndrome. Read More

    Advances in understanding the pathogenesis of congenital erythropoietic porphyria.
    Br J Haematol 2016 05 11;173(3):365-79. Epub 2016 Mar 11.
    U.O. di Medicina Interna, Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milano, Italy.
    Congenital erythropoietic porphyria (CEP) is a rare genetic disease resulting from the remarkable deficient activity of uroporphyrinogen III synthase, the fourth enzyme of the haem biosynthetic pathway. This enzyme defect results in overproduction of the non-physiological and pathogenic porphyrin isomers, uroporphyrin I and coproporphyrin I. The predominant clinical characteristics of CEP include bullous cutaneous photosensitivity to visible light from early infancy, progressive photomutilation and chronic haemolytic anaemia. Read More

    A Rare Case of Puberty Onset Congenital Erythropoietic Porphyria with Ophthalmological Manifestations.
    Middle East Afr J Ophthalmol 2016 Jan-Mar;23(1):160-2
    Department of Ophthalmology, Nil Ratan Sircar (NRS) Medical College and Hospital, Kolkata, West Bengal, India.
    A 27-year-old male patient was presented with foreign body sensation in both the eyes for 2 years duration and blisters followed by scarring and pigmentation in the photo-exposed areas of the body over the previous 12 years. His urine was reddish colored for the previous year. On examination, there was scarring, hyper-pigmentation of photo-exposed parts of the body along with resorption of the distal phalanges of fingers in both hands except the smallest digit which had onycholysis. Read More

    The emerging role of GATA transcription factors in development and disease.
    Expert Rev Mol Med 2016 Mar 8;18:e3. Epub 2016 Mar 8.
    Department of Pathology,GROW - School for Oncology and Developmental Biology,Maastricht University Medical Center,Maastricht,The Netherlands.
    The GATA family of transcription factors consists of six proteins (GATA1-6) which are involved in a variety of physiological and pathological processes. GATA1/2/3 are required for differentiation of mesoderm and ectoderm-derived tissues, including the haematopoietic and central nervous system. GATA4/5/6 are implicated in development and differentiation of endoderm- and mesoderm-derived tissues such as induction of differentiation of embryonic stem cells, cardiovascular embryogenesis and guidance of epithelial cell differentiation in the adult. Read More

    Scleral necrosis in congenital erythropoietic porphyria: A case report and review of the literature.
    Oman J Ophthalmol 2015 Sep-Dec;8(3):200-4
    Department of Cornea and Ocular Surface Disorders, Sankara Nethralaya, Chennai, Tamil Nadu, India.
    A 28-year-old presented with complaints of severe pain and redness in the left eye since 2 weeks. He had similar complaints in the right eye 2 years back for which he had undergone a scleral patch graft. Best corrected visual acuity was 20/20 in both eyes. Read More

    A precursor-inducible zebrafish model of acute protoporphyria with hepatic protein aggregation and multiorganelle stress.
    FASEB J 2016 05 2;30(5):1798-810. Epub 2016 Feb 2.
    Department of Molecular and Integrative Physiology, Department of Internal Medicine, and Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA
    Protoporphyria is a metabolic disease that causes excess production of protoporphyrin IX (PP-IX), the final biosynthetic precursor to heme. Hepatic PP-IX accumulation may lead to end-stage liver disease. We tested the hypothesis that systemic administration of porphyrin precursors to zebrafish larvae results in protoporphyrin accumulation and a reproducible nongenetic porphyria model. Read More

    A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease.
    Folia Biol (Praha) 2015 ;61(6):227-32
    Department of Paediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic.
    Erythropoietic protoporphyria (EPP), a chronic erythropoietic porphyria, is characterized by excess accumulation of protoporphyrin, particularly in erythroid cells. EPP inheritance is complex, almost always associated with two molecular defects. In most EPP patients, clinical expression requires coinheritance of a private ferrochelatase (FECH) mutation trans- to a hypomorphic FECH*IVS3-48C allele. Read More

    [Erythropoietic protoporphyria : Clinical manifestations, diagnosis and new therapeutic possibilities].
    Hautarzt 2016 Mar;67(3):211-5
    Hautklinik und Europäisches Porphyriezentrum, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, 40225, Düsseldorf, Moorenstr. 5, Deutschland.
    Background: Erythropoietic protoporphyria, the second most common type of the cutaneous porphyrias, is due to an enzymatic deficiency of ferrochelatase, the last enzyme in heme biosynthesis. The enzyme defect leads to an accumulation of protoporphyrin IX in erythrocytes and an elevated excretion of this metabolite in the feces.

    Clinical Presentation: Usually, disease onset is in early infancy, characterized by increased photosensitivity. Read More

    [Congenital erythropoietic porphyria : An update].
    Hautarzt 2016 Mar;67(3):216-20
    Hautklinik und Europäisches Porphyriezentrum, Universitätsklinikum der Heinrich Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
    Background: Congenital erythropoetic porphria is a very rare type of autosomal recessive nonacute porphyria. Homozygous or compound heterozygous mutations in the uroporphyrinogen III consynthase gene cause a marked enzymatic deficiency of uroporphyrinogen III consynthase, the fourth enzyme along the heme biosynthetic pathway.

    Clinical Presentation: Clinically, affected patients are characterized by a moderate to severe photosensitivity. Read More

    Biology of Heme in Mammalian Erythroid Cells and Related Disorders.
    Biomed Res Int 2015 18;2015:278536. Epub 2015 Oct 18.
    Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan ; Molecular Hematology/Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.
    Heme is a prosthetic group comprising ferrous iron (Fe(2+)) and protoporphyrin IX and is an essential cofactor in various biological processes such as oxygen transport (hemoglobin) and storage (myoglobin) and electron transfer (respiratory cytochromes) in addition to its role as a structural component of hemoproteins. Heme biosynthesis is induced during erythroid differentiation and is coordinated with the expression of genes involved in globin formation and iron acquisition/transport. However, erythroid and nonerythroid cells exhibit distinct differences in the heme biosynthetic pathway regulation. Read More

    Congenital Erythropoietic Porphyria With Calcific Constrictive Pericarditis: A Case Report and Brief Review of Literature.
    World J Pediatr Congenit Heart Surg 2015 Oct;6(4):646-9
    Cardiothoracic Sciences Centre, All India Institute of Medical Sciences, New Delhi, India.
    An 18-year-old boy with congenital erythropoietic porphyria and calcific constrictive pericarditis underwent total pericardiectomy. The cause of pericardial calcification could be deposition of porphyrins in the pericardium. Surgical importance of this rare condition is highlighted. Read More

    1 OF 18